Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9H6R6

UPID:
ZDHC6_HUMAN

ALTERNATIVE NAMES:
Stearoyltransferase ZDHHC6; Transmembrane protein H4; Zinc finger DHHC domain-containing protein 6; Zinc finger protein 376

ALTERNATIVE UPACC:
Q9H6R6; D3DRB6; Q53G45; Q96IV7; Q9H605

BACKGROUND:
The enzyme Palmitoyltransferase ZDHHC6, recognized for its roles in palmitoylation and stearoylation, impacts protein interactions and signaling pathways. By modifying proteins like CALX for glycosylated protein folding and regulating ITPR1 stability in immune cells, ZDHHC6 is pivotal in cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Palmitoyltransferase ZDHHC6 offers a promising avenue for developing novel therapeutic approaches. Its critical role in protein processing and signaling underscores its potential as a target in drug discovery and development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.